Immix Biopharma, Inc. Common Stock
Veridion Score
Composite trend over time
Why is IMMX moving today?
Immix Biopharma Inc is engaged in the discovery and development of novel cell therapies for hematologic malignancies (blood cancers) and other indications. It is a clinical-stage biopharmaceutical company developing a novel class of Tissue-Specific Therapeutics TM in oncology and inflammation. Its TME Normalization Technology allows drug candidates to circulate in the bloodstream, exit through tumor blood vessels and simultaneously attack all components of the TME. Its product candidates include CAR-T NXC-201 for autoimmune diseases, and IMX-110 for treatment of soft tissue sarcoma.
Reported fields plus Veridion-computed history. Unsourced tiles are omitted.
Warehouse intelligence for IMMX.
IMMX insider activity
Immix Biopharma, Inc. Common Stock
No multi-insider buying cluster in the last 90 days
Mixed: Not disclosed across loaded Form 4 rows.
Loaded official disclosures do not show all three sources aligned on this ticker.
The current Form 4 feed did not return value-bearing open-market rows for IMMX.
IMMX contract awards, year to date.
Public federal awards linked to this ticker.
IMMX lobbying filings, year to date.
Registered lobbying filings matched to Immix Biopharma, Inc. Common Stock.